Start-Up Mitochon's Repurposed Drug Targets Mitochondria For Orphan Diseases
Executive Summary
Emerging Company Profile: Mitochon Pharmaceuticals, founded in 2014, focuses on mitochondrial therapeutics with emphasis on neurodegenerative diseases. CEO Robert Alsonso outlines the biotech's corporate strategy now that an orphan drug designation has been given to lead drug MP-101 for Huntington’s Disease.